



ROSE[®]

RGA Group Research

Getting a Grip on High-Cost Drugs



As payers continue to struggle with the surge in both the volume and cost of specialty drugs, RGA Group Research and ROSE[®] Program teams have identified a list of 180+ costly specialty drugs* with their associated estimated costs.

One of The Most Expensive Drivers of High-Cost Drugs

Hemophilia & Bleeding Disorders

RGA has seen a significant increase in the number of claims exceeding \$2 million since 2005; one significant driver of these claims is hemophilia. While the drugs for hemophilia and other bleeding disorders are expensive, inappropriate management is much more costly. RGA's ROSE Program helps clients more effectively manage these difficult cases.



Top 10 Most Expensive Drugs

1. Glybera (not FDA-approved)

Genetic Diseases

2. Raviciti

Genetic Diseases

3. Lumizyme

Lysosomal Storage Disorders

4. Carbaglu

Genetic Diseases

5. Actimmune

Genetic Disease

6. Soliris

Hemolytic Disorders

7. Alprolix

Hemophilia & Related

8. Idelvion

Hemophilia & Related

9. Naglazyme

Lysosomal Storage Disorders

Of 183 high-cost* specialty drugs studied



69%

exceeded \$100,000
average annual
wholesale acquisition
cost (WAC)

Of 183 high-cost* specialty drugs studied

26%

exceeded \$200,000
average annual
wholesale acquisition
cost (WAC)

